# Sun Pharma wins US antitrust appeal over Lipitor deal 2026-08-17T17:09:13+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet Sun Pharmaceutical Industries has secured a favourable verdict in the United States antitrust litigation related to a 2008 patent settlement agreement with Pfizer over generic Lipitor (Atorvastatin). The United States Court of Appeals for the Third Circuit affirmed the District Court's order granting summary judgment entirely in favour of the company and its subsidiaries. The appellate court also upheld the District Court's orders denying class certification to the plaintiffs. The antitrust plaintiffs had alleged that the settlement agreement unlawfully delayed generic competition for Lipitor. Sun Pharma stated that the decision brings the litigation substantially to a close, subject to any further remedies available to the plaintiffs under applicable law. The judgment was announced on Monday, August 17, 2026. ## Coverage - thehindu.com This story was synthesised by AI from the source linked above. Tags: Lipitor, Pfizer, Sun Pharma Canonical: https://indianopinion.org/sun-pharma-wins-us-antitrust-appeal-over-lipitor-deal/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/sun-pharma-wins-us-antitrust-appeal-over-lipitor-deal/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes. How this brief was made: an AI model read the report linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/